Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Aparna Kalyan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1686-093X; OpenAlex author ID A5114082408. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Co-author DOI 10.3390/cancers18132037↗
  2. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Co-author DOI 10.1038/s41416-023-02344-5↗
  3. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. First author DOI 10.1634/theoncologist.2019-0473↗
  4. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  5. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Last author DOI 10.1155/2018/6314392↗
  6. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. First author DOI 10.21037/jgo.2017.01.23↗
  7. Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer? Co-author DOI 10.1200/jop.2016.015883↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Al B. Benson · 5 shared papers, 2016–2026 · strength 0.78
  2. Sheetal Mehta Kircher · 3 shared papers, 2020–2026 · strength 0.57
  3. Mary F. Mulcahy · 3 shared papers, 2020–2026 · strength 0.57
  4. Devalingam Mahalingam · 2 shared papers, 2023–2026 · strength 0.45
  5. Tarık Demir · 1 shared paper, 2026 · strength 0.29
  6. Dılşa Mızrak Kaya · 1 shared paper, 2026 · strength 0.29
  7. Bin Zhang · 1 shared paper, 2023 · strength 0.16
  8. Suneel Deepak Kamath · 1 shared paper, 2020 · strength 0.13
  9. Halla Sayed Nimeiri · 1 shared paper, 2020 · strength 0.13
  10. Chrystal Ursula Louis · 1 shared paper, 2019 · strength 0.09
  11. Caio Rocha‐Lima · 1 shared paper, 2019 · strength 0.09
  12. Allyson J. Ocean · 1 shared paper, 2019 · strength 0.09
  13. Muhammad Wasif Saif · 1 shared paper, 2019 · strength 0.09
  14. Diane M. Simeone · 1 shared paper, 2019 · strength 0.09
  15. Vaibhav Sahai · 1 shared paper, 2019 · strength 0.09
  16. Vincent J. Picozzi · 1 shared paper, 2019 · strength 0.09
  17. Philip A. Philip · 1 shared paper, 2019 · strength 0.09
  18. Vahid Yaghmai · 1 shared paper, 2018 · strength 0.08
  19. Rubens Barros Costa · 1 shared paper, 2018 · strength 0.08
  20. Weijing Sun · 1 shared paper, 2017 · strength 0.07
  21. Herbert J. Zeh · 1 shared paper, 2017 · strength 0.07
  22. Khanh T. Nguyen · 1 shared paper, 2017 · strength 0.07
  23. Nathan Bahary · 1 shared paper, 2017 · strength 0.07
  24. Aatur Dilip Singhi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.